Verona Pharma plc - American Depositary Share (VRNA): Price and Financial Metrics


Verona Pharma plc - American Depositary Share (VRNA): $4.48

0.02 (+0.45%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VRNA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VRNA POWR Grades


  • VRNA scores best on the Sentiment dimension, with a Sentiment rank ahead of 99.98% of US stocks.
  • The strongest trend for VRNA is in Sentiment, which has been heading up over the past 157 days.
  • VRNA ranks lowest in Momentum; there it ranks in the 12th percentile.

VRNA Stock Summary

  • Of note is the ratio of Verona Pharma plc's sales and general administrative expense to its total operating expenses; merely 13.77% of US stocks have a lower such ratio.
  • For VRNA, its debt to operating expenses ratio is greater than that reported by merely 9.97% of US equities we're observing.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.24 for Verona Pharma plc; that's greater than it is for only 14.55% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Verona Pharma plc are IMTX, ARVN, ACRS, ARGX, and CUE.
  • Visit VRNA's SEC page to see the company's official filings. To visit the company's web site, go to www.veronapharma.com.

VRNA Valuation Summary

  • 500 - Internal server error
  • VRNA's EV/EBIT ratio has moved up 16 over the prior 53 months.
  • VRNA's EV/EBIT ratio has moved up 16 over the prior 53 months.

Below are key valuation metrics over time for VRNA.

Stock Date P/S P/B P/E EV/EBIT
VRNA 2021-08-31 NA 2.3 -4.3 -2.7
VRNA 2021-08-30 NA 2.3 -4.3 -2.8
VRNA 2021-08-27 NA 2.4 -4.5 -3.0
VRNA 2021-08-26 NA 2.4 -4.6 -3.1
VRNA 2021-08-25 NA 2.4 -4.6 -3.0
VRNA 2021-08-24 NA 2.3 -4.3 -2.7

VRNA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VRNA has a Quality Grade of C, ranking ahead of 31.46% of graded US stocks.
  • VRNA's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
  • PPBT, TEVA, and PTE are the stocks whose asset turnover ratios are most correlated with VRNA.

The table below shows VRNA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA -8.524
2021-03-31 0 NA -14.982
2020-12-31 0 NA -21.674
2020-09-30 0 NA -13.707
2020-06-30 0 NA -6.646
2020-06-30 0 NA -6.646

VRNA Stock Price Chart Interactive Chart >

Price chart for VRNA

VRNA Price/Volume Stats

Current price $4.48 52-week high $7.87
Prev. close $4.46 52-week low $3.41
Day low $4.28 Volume 30,400
Day high $4.50 Avg. volume 85,344
50-day MA $4.35 Dividend yield N/A
200-day MA $5.24 Market Cap 270.45M

Verona Pharma plc - American Depositary Share (VRNA) Company Bio


Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual phosphodiesterase 3 and 4 inhibitor, which is in Phase II clinical trial for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma. Verona Pharma plc is based in London, the United Kingdom.


VRNA Latest News Stream


Event/Time News Detail
Loading, please wait...

VRNA Latest Social Stream


Loading social stream, please wait...

View Full VRNA Social Stream

Latest VRNA News From Around the Web

Below are the latest news stories about Verona Pharma plc that investors may wish to consider to help them evaluate VRNA as an investment opportunity.

Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth quarter and full year ended December 31, 2021 on Thursday, March 3, 2022 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

GlobeNewswire | February 17, 2022

Verona Pharma: First Inhaled Product Candidate Combining Anti-Inflammatory And Bronchodilator Effects, A Potential Blockbuster

Verona Pharma (VRNA) was founded in 2005 and is based in London, U.K. The company’s lead product candidate is Ensifentrine, an inhaled PDE3, and PDE4 inhibitor, which is being developed as a maintenance treatment for chronic obstructive respiratory disease, COPD (after tiotropium). The advantage of dual PDE3 and PDE4 inhibition...

Bhavneesh Sharma on Seeking Alpha | February 4, 2022

Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD

Top-line Data Expected in the Third Quarter of 2022LONDON and RALEIGH, N.C., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces it has completed patient enrollment with more than 800 subjects randomized in the ENHANCE-2 trial, evaluating ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”). Top-line data are expect

Yahoo | January 24, 2022

Verona Pharma (VRNA) Gets a Buy Rating from Wedbush

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Verona Pharma (VRNA – Research Report), with a price target of $25.00. The company's shares closed last Wednesday at $6.88. According to TipRanks.com, Moussatos has 0 stars on 0-5 stars ranking scale with an average return of -4.5% and a 33.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, BioMarin Pharmaceutical, and Pacira Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Verona Pharma with a $21.60 average price target, representing a 206.4% upside. In a report issued on January 3, H.C.

Christine Brown on TipRanks | January 6, 2022

Analysts Offer Insights on Healthcare Companies: Spectrum Pharmaceuticals (SPPI), Sensus Healthcare (SRTS) and Verona Pharma (VRNA)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Spectrum Pharmaceuticals (SPPI – Research Report), Sensus Healthcare (SRTS – Research Report) and Verona Pharma (VRNA – Research Report) with bullish sentiments. Spectrum Pharmaceuticals (SPPI) In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Spectrum Pharmaceuticals, with a price target of $10.00. The company's shares closed last Wednesday at $1.27. According to TipRanks.com, White is a 4-star analyst with an average return of -22.1% and a 20.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Oncternal Therapeutics, and Inovio Pharmaceuticals.

Christine Brown on TipRanks | January 6, 2022

Read More 'VRNA' Stories Here

VRNA Price Returns

1-mo 7.18%
3-mo -20.28%
6-mo -6.28%
1-year -25.95%
3-year -24.07%
5-year -68.34%
YTD -33.33%
2021 -4.00%
2020 21.74%
2019 N/A
2018 0.00%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6571 seconds.